ravulizumab
Term · Oncology and biomedicine · MLC-T-ONC-007231
A drug used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare red blood cell disorder) and adults and children aged 1 month and older with atypical hemolytic uremic syndrome (a very rare disorder in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. Ravulizumab binds to an immune system protein called C5. This may help keep red blood cells from breaking down and blood clots from forming. Ravulizumab is a type of monoclonal antibody. Also called Ultomiris.
| Identifier | MLC-T-ONC-007231 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Ultomiris |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007231",
"term": "ravulizumab",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare red blood cell disorder) and adults and children aged 1 month and older with atypical hemolytic uremic syndrome (a very rare disorder in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. Ravulizumab binds to an immune system protein called C5. This may help keep red blood cells from breaking down and blood clots from forming. Ravulizumab is a type of monoclonal antibody. Also called Ultomiris.",
"synonyms": [
"Ultomiris"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ravulizumab/"
}
Record 14,095 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.